Danna Jennings

9.7k citations

81 papers · 3.2k indexed · h-index 33

Neurology top 0.5%
Physiology top 5%
Cellular and Molecular Neuroscience top 2%
Psychiatry and Mental health top 2%
Molecular Biology

Co-authors: Kenneth Marek John Seibyl Shirley Eberly Andrew Siderowf David Oakes Gilles Tamagnan Mark A. Mintun Abhinay D. Joshi
Topics: Parkinson's Disease Mechanisms and Treatments (42 papers)Neurological disorders and treatments (37 papers)Botulinum Toxin and Related Neurological Disorders (9 papers)
Cited by: Neurology Cellular and Molecular Neuroscience Psychiatry and Mental health
Journals: NeuroImage Brain Neurology
Partner nations: United States Canada Switzerland

In The Last Decade

Danna Jennings

79 papers receiving 3.1k citations

Peers

Countries citing papers authored by Danna Jennings

Since Specialization

Citations

This map shows the geographic impact of Danna Jennings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danna Jennings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danna Jennings more than expected).

Fields of papers citing papers by Danna Jennings

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danna Jennings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danna Jennings. The network helps show where Danna Jennings may publish in the future.

Co-authorship network of co-authors of Danna Jennings

This figure shows the co-authorship network connecting the top 25 collaborators of Danna Jennings. A scholar is included among the top collaborators of Danna Jennings based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danna Jennings. Danna Jennings is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Characterization of [¹⁸F]T-008, a Cholesterol 24-Hydroxylase PET Ligand: Dosimetry, Kinetic Modeling, Variability, and Soticlestat Occupancy 2023 ·Journal of Nuclear Medicine ·Cristian Constantinescu,Terry Brown,Shining Wang,Wei Yin,Olivier Barret,Danna Jennings,(unknown)	2
2	Reduced Expression of Cerebral Metabotropic Glutamate Receptor Subtype 5 in Men with Fragile X Syndrome 2020 ·Brain Sciences ·James Robert Brašić,Ayon Nandi,David Russell,Danna Jennings,Olivier Barret,Anil Mathur,Keith J. Slifer,Thomas W. Sedlak,(unknown),(unknown),Pankhuri Vyas,John Seibyl,Elizabeth Berry‐Kravis,Dean F. Wong,Dejan B. Budimirovic	12
3	Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4) 2018 ·Journal of Parkinson s Disease ·Lana M. Chahine,Thomas G. Beach,(unknown),Chelsea Caspell‐Garcia,Christopher S. Coffey,Michael C. Brumm,Charles H. Adler,Geidy E. Serrano,Carly Linder,Sherri Mosovsky,Tatiana Foroud,(unknown),Dixie Ecklund,John Seibyl,Danna Jennings,Vanessa Arnedo,Lindsey Riley,Kuldip D. Dave,Brit Mollenhauer,(unknown)	15
4	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition 2017 ·Brain ·Michael J. Pontecorvo,Michael D. Devous,Michael Navitsky,Ming‐Chi Lu,Stephen Salloway,Frederick W. Schaerf,Danna Jennings,Anupa Arora,Anne McGeehan,Nathaniel C. Lim,Hui Xiong,Abhinay D. Joshi,Andrew Siderowf,Mark A. Mintun,(unknown)	263
5	Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease 2016 ·Parkinson s Disease ·William Seiple,Danna Jennings,Richard B. Rosen,(unknown),(unknown),Nora Fagan,Mark Forrest Gordon	4
6	Assessment of Parkinson disease progression using 123- I I-Ioflupane SPECT: Update from the Parkinson Progression Marker Initiative Trial (I11-5C) 2015 ·Neurology ·John Seibyl,Danna Jennings,Kenneth Marek	1
7	In Vivo Assessment and Dosimetry of 2 Novel PDE10A PET Radiotracers in Humans: ¹⁸F-MNI-659 and ¹⁸F-MNI-654 2014 ·Journal of Nuclear Medicine ·Olivier Barret,David Thomae,Adriana Tavares,David Alagille,Caroline Papin,Rikki N. Waterhouse,Timothy J. McCarthy,Danna Jennings,Kenneth Marek,David Russell,John Seibyl,Gilles Tamagnan	51
8	Brain distribution of BZM055, an analog of fingolimod (FTY720), in human 2012 ·Multiple Sclerosis Journal ·Gilles Tamagnan,Adriana Tavares,Olivier Barret,D Alagille,John Seibyl,Kenneth Marek,R. P. Maguire,Emmanuelle Briard,Robert Schmouder,(unknown),Danna Jennings	10
9	Impaired olfaction and other prodromal features in the Parkinson At‐Risk Syndrome study 2012 ·Movement Disorders ·Andrew Siderowf,Danna Jennings,Shirley Eberly,David Oakes,Keith A. Hawkins,(unknown),Matthew B. Stern,Kenneth Marek,(unknown)	144
10	Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects 2012 ·Journal of Nuclear Medicine ·Abhinay D. Joshi,Michael J. Pontecorvo,(unknown),Alan Carpenter,Danna Jennings,Carl Sadowsky,Lee P. Adler,(unknown),John Seibyl,Anupa Arora,Krishnendu Saha,Jason Burns,Mark Lowrey,Mark A. Mintun,Daniel Skovronsky,(unknown)	301
11	First in vivo assessment of two PDE10 tracers [18F]MNI654 and [18F]MNI659 2012 ·Olivier Barret,David Thomae,David Alagille,Hsiaoju Lee,Caroline Papin,Ronald M. Baldwin,Danna Jennings,Kenneth Marek,John Seibyl,Gilles Tamagnan	9
12	Neuroimaging Over the Course of Parkinson's Disease: From Early Detection of the At-Risk Patient to Improving Pharmacotherapy of Later-Stage Disease 2012 ·Seminars in Nuclear Medicine ·John Seibyl,David Russell,Danna Jennings,Kenneth Marek	17
13	Molecular PET imaging in multicenter Alzheimer’s therapeutic trials: current trends and implementation strategies 2011 ·Expert Review of Neurotherapeutics ·John Seibyl,I. George Zubal,Danna Jennings,Kenneth Marek,P. Murali Doraiswamy	4
14	Occupational exposure to PCBs reduces striatal dopamine transporter densities only in women: A β-CIT imaging study 2010 ·Neurobiology of Disease ·Richard F. Seegal,Kenneth Marek,John Seibyl,Danna Jennings,Eric Molho,Donald S. Higgins,Stewart A. Factor,Edward F. Fitzgerald,Elaine A. Hills,Susan Korrick,Mary S. Wolff,Richard F. Haase,Andrew C. Todd,Patrick J. Parsons,Robert J. McCaffrey	41
15	FMR1 gene expansion and scans without evidence of dopaminergic deficits in parkinsonism patients 2010 ·Parkinsonism & Related Disorders ·Deborah J. Hall,Danna Jennings,John Seibyl,F. Tassone,Kenneth Marek	19
16	Biomarkers for Parkison's disease: Tools to assess Parkinson's disease onset and progression 2009 ·Annals of Neurology ·Kenneth Marek,Danna Jennings,Gilles Tamagnan,John Seibyl	48
17	Phenotypic spectrum and sex effects in eleven myoclonus‐dystonia families with ε‐sarcoglycan mutations 2008 ·Movement Disorders ·Deborah Raymond,Rachel Saunders‐Pullman,Patrícia de Carvalho Aguiar,Birgitt Schüle,Norman Kock,Jennifer Friedman,Juliette Harris,Blair Ford,Steven J. Frucht,Gary A. Heiman,Danna Jennings,Dana Doheny,Mitchell F. Brin,(unknown),Trisha Multhaupt‐Buell,Anthony E. Lang,Roger Kurlan,Christine Klein,Laurie J. Ozelius,Susan Bressman	35
18	Interest in predictive testing for Parkinson's disease: Impact of neuroprotective therapy 2007 ·Parkinsonism & Related Disorders ·Nabila Dahodwala,James L. Connolly,Jennifer Farmer,M. B. Stern,Danna Jennings,Andrew Siderowf	15
19	[¹²³I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy 2001 ·Movement Disorders ·Andrea Varrone,Kenneth Marek,Danna Jennings,Robert B. Innis,John Seibyl	126
20	Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31 1999 ·Annals of Neurology ·Torbjoern G. Nygaard,Deborah Raymond,Caiping Chen,Ichizo Nishino,Paul Greene,Danna Jennings,Gary A. Heiman,(unknown),(unknown),Patricia Kramer,Laurie J. Ozelius,Susan Bressman	71

About Danna Jennings

Danna Jennings is a scholar working on Neurology, Cellular and Molecular Neuroscience and Cognitive Neuroscience, having authored 81 papers that have together received 3.2k indexed citations. Recurring topics across this work include Parkinson's Disease Mechanisms and Treatments (42 papers), Neurological disorders and treatments (37 papers) and Botulinum Toxin and Related Neurological Disorders (9 papers). The work is most often cited by research in Neurology (1.8k citations), Cellular and Molecular Neuroscience (720 citations) and Psychiatry and Mental health (584 citations). Danna Jennings has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Kenneth Marek, John Seibyl, Shirley Eberly, Andrew Siderowf, David Oakes, Gilles Tamagnan, Mark A. Mintun, Abhinay D. Joshi, Anupa Arora and Michael J. Pontecorvo. Their work appears in journals such as NeuroImage, Brain and Neurology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact